Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Sana Biotechnology, Inc.NASDAQ: SANA
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 276.86M shares rose 16.5% year over year, ahead of the +9.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +16.5% holds above the trailing-twelve-month pace of +9.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 253.23M USD
- Year-over-year change
- +9.7%
- 4-year CAGR
- +11.1%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 253.23M | +9.7% |
| FY2024 | 2024-12-31 | 230.89M | +18.7% |
| FY2023 | 2023-12-31 | 194.54M | +3.3% |
| FY2022 | 2022-12-31 | 188.34M | +13.2% |
| FY2021 | 2021-12-31 | 166.43M | — |
Weighted Avg Shares (Diluted) vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 weighted avg shares (diluted) of 257.25M shares is the highest of the 11 companies compared; the peer median is 99.29M shares.
- Its year-over-year change of +9.0% is the 6th highest of 11, against a peer median of +8.9%.
- Over three fiscal years its annual growth of +10.4% compares with a peer median of +12.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 257.25M | +9.0% | +10.4% | |
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Sep 2026 | 189.27M | +2.9% | +5.0% | |
| LTM Mar 2026 | 119.09M | +1.0% | +7.1% | |
| LTM Mar 2026 | 110.2M | +9.3% | +12.1% | |
| LTM Jun 2026 | 103.77M | +17.0% | +12.2% | |
| LTM Sep 2026 | 94.81M | +8.4% | +5.0% | |
| LTM Mar 2026 | 86.45M | +4.3% | +14.4% | |
| LTM Mar 2026 | 59.11M | +2.4% | +8.2% | |
| LTM Mar 2026 | 13.17M | +49.9% | +46.1% | |
| LTM Mar 2026 | 12.13M | +60.9% | +63.6% | |
| Peer median (excluding SANA) | 99.29M | +8.9% | +12.1% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| Weighted Avg Shares | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
| Weighted Avg Shares (Diluted) | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.